8h agoInvesting.com Analyst RatingsBULLISH 56Analyst
H.C. Wainwright reiterates Legend Biotech stock rating on durability data
H.C. Wainwright reiterates Legend Biotech stock rating on durability data
Archived explainer. For the current picture see today's LEGN page.
Why Is LEGEND BIOTECH CORP ADR (LEGN) Stock Up Today?
By the Top Tier Newswire AI Desk · September 30, 2026 at 11:55 AM ET · reviewed against 3 wire stories
LEGEND BIOTECH CORP ADR (LEGN) is up +6.17% in the latest session. Our newswire has captured 3 stories on LEGN across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why LEGN stock is up today
Legend Biotech ADR (LEGN) rose 6.17% to $19.98 in early trading, driven by renewed analyst optimism and a series of developments in the company's leadership and clinical data. The stock opened with a modest 0.5% gap up and climbed steadily through the session, reaching a high of $20.00. The move follows a reiteration of a Buy rating by H.C. Wainwright, based on durability data from the company’s clinical trials.
What Happened
H.C. Wainwright has reaffirmed its positive stance on Legend Biotech, citing the durability of results from its CARVYKTI therapy. The firm maintains a $65 price target for the stock, signaling long-term confidence in the company's potential. Meanwhile, external reports indicate that Robinhood is integrating AI trading strategies and a social feature into its Legend platform, which may increase visibility and engagement for the stock.
Legend Biotech also recently announced the appointment of Ingrid Zhang as CEO, succeeding Alan Bash. This leadership change, combined with the 50% progression-free survival rate reported in the CARTITUDE-2 trial at five years, has added to the stock's momentum. Barclays also adjusted its price target to $74 while maintaining an Overweight rating, further reinforcing the positive sentiment.
What The Data Shows
The stock has gained 12.2% over the last eight sessions, moving from $16.94 to $19.01. Intraday volume of 0.8 million shares is 0.3 times the 3-month average, suggesting moderate participation. The stock is currently trading within its 52-week range of $16.24 to $37.50, having printed one fresh 52-week low and 15 fresh 52-week highs on September 30. Recent insider transactions include two sales totaling $138K, with no insider buys reported in the last 90 days.
What To Watch
Investors should monitor the company’s upcoming earnings report, if any, and continue to track the breadth of analyst coverage. The stock’s performance may also be influenced by further developments in its clinical pipeline and leadership transition.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LEGN by the numbers
Last: $19.98Session: +6.17%7 sessions: +12.22%Coverage: 3 stories / 2 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $3.6B52w: $16.24 to $37.50
The headlines behind the move
20h agoThe FlyBULLISH 58Product/PR
Robinhood says integrating Robinhood Social into app and Legend
20h agoThe FlyBULLISH 58Product/PR
Robinhood says will rollout AI trading strategies in Legend platform
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on LEGN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LEGN move explainers: 2026-09-30 · 2026-08-18